Published in Dev Comp Immunol on July 12, 2005
The potential of antimicrobial peptides as biocides. Int J Mol Sci (2011) 0.99
Quo vadis venomics? A roadmap to neglected venomous invertebrates. Toxins (Basel) (2014) 0.83
Earthworm-derived pore-forming toxin lysenin and screening of its inhibitors. Toxins (Basel) (2013) 0.76
Microbial environment affects innate immunity in two closely related earthworm species Eisenia andrei and Eisenia fetida. PLoS One (2013) 0.75
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 7.15
Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature (2003) 4.33
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res (2010) 4.25
Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol (2002) 3.89
Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A (2009) 3.01
Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol (2005) 2.75
FIZZ1 and Ym as tools to discriminate between differentially activated macrophages. Dev Immunol (2002) 2.36
Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol (2004) 2.30
Alternatively activated macrophages during parasite infections. Trends Parasitol (2004) 2.01
Functional identification of the alveolar edema reabsorption activity of murine tumor necrosis factor-alpha. Am J Respir Crit Care Med (2003) 1.98
Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology (2006) 1.96
Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. Blood (2009) 1.92
Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol (2003) 1.91
Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol (2005) 1.86
Trypanosoma brucei modifies the tsetse salivary composition, altering the fly feeding behavior that favors parasite transmission. PLoS Pathog (2010) 1.77
Tip-DC development during parasitic infection is regulated by IL-10 and requires CCL2/CCR2, IFN-gamma and MyD88 signaling. PLoS Pathog (2010) 1.70
Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect Dis (2006) 1.68
Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood (2006) 1.65
Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem (2003) 1.54
Retracted Heterologous expression, purification and characterization of nitrilase from Aspergillus niger K10. BMC Biotechnol (2011) 1.47
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res (2013) 1.46
Efficient cancer therapy with a nanobody-based conjugate. Cancer Res (2004) 1.46
Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med (2008) 1.45
Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood (2006) 1.43
Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol (2011) 1.41
MyD88-dependent activation of B220-CD11b+LY-6C+ dendritic cells during Brucella melitensis infection. J Immunol (2007) 1.39
Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer (2002) 1.36
Myeloid-derived suppressor cells in parasitic infections. Eur J Immunol (2010) 1.36
IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection. J Immunol (2009) 1.35
Alternatively activated macrophages in protozoan infections. Curr Opin Immunol (2007) 1.30
Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther (2005) 1.26
Antiprotozoan and Antiviral Activities of Non-cytotoxic Truncated and Variant Analogues of Mussel Defensin. Evid Based Complement Alternat Med (2004) 1.24
Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol (2003) 1.23
The induction of a type 1 immune response following a Trypanosoma brucei infection is MyD88 dependent. J Immunol (2005) 1.23
The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur J Immunol (2005) 1.21
Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res (2012) 1.20
Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med (2006) 1.20
Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A (2003) 1.19
Adenylate cyclases of Trypanosoma brucei inhibit the innate immune response of the host. Science (2012) 1.19
Secretory leukocyte protease inhibitor in cancer development. Ann N Y Acad Sci (2004) 1.18
Alternatively activated myeloid cells limit pathogenicity associated with African trypanosomiasis through the IL-10 inducible gene selenoprotein P. J Immunol (2008) 1.16
Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood (2011) 1.15
Interferon-gamma and nitric oxide in combination with antibodies are key protective host immune factors during trypanosoma congolense Tc13 Infections. J Infect Dis (2006) 1.12
SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol (2008) 1.12
The role of B-cells and IgM antibodies in parasitemia, anemia, and VSG switching in Trypanosoma brucei-infected mice. PLoS Pathog (2008) 1.09
African trypanosomiasis: naturally occurring regulatory T cells favor trypanotolerance by limiting pathology associated with sustained type 1 inflammation. J Immunol (2007) 1.09
P75 tumor necrosis factor-receptor shedding occurs as a protective host response during African trypanosomiasis. J Infect Dis (2004) 1.08
Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med (2010) 1.07
Domains and maturation processes that regulate the activity of ADAMTS-2, a metalloproteinase cleaving the aminopropeptide of fibrillar procollagens types I-III and V. J Biol Chem (2005) 1.06
Myeloid-derived suppressor cells infiltrate the heart in acute Trypanosoma cruzi infection. J Immunol (2011) 1.05
Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol (2005) 1.04
Pivotal Advance: Arginase-1-independent polyamine production stimulates the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory genes. J Leukoc Biol (2012) 1.04
Macrophage reprogramming by mycolic acid promotes a tolerogenic response in experimental asthma. Am J Respir Crit Care Med (2006) 1.01
Tsetse fly saliva biases the immune response to Th2 and induces anti-vector antibodies that are a useful tool for exposure assessment. Int J Parasitol (2006) 1.01
High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLoS Pathog (2011) 1.01
In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med (2010) 0.99
African trypanosomosis: from immune escape and immunopathology to immune intervention. Vet Parasitol (2007) 0.98
Transcriptome analysis of monocyte-HIV interactions. Retrovirology (2010) 0.98
SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med (2013) 0.97
Expression and extracellular release of a functional anti-trypanosome Nanobody® in Sodalis glossinidius, a bacterial symbiont of the tsetse fly. Microb Cell Fact (2012) 0.97
Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens. J Immunol Methods (2007) 0.97
Tumor necrosis factor (TNF) receptor-1 (TNFp55) signal transduction and macrophage-derived soluble TNF are crucial for nitric oxide-mediated Trypanosoma congolense parasite killing. J Infect Dis (2007) 0.96
A glycosylphosphatidylinositol-based treatment alleviates trypanosomiasis-associated immunopathology. J Immunol (2007) 0.96
Role of iron homeostasis in trypanosomiasis-associated anemia. Immunobiology (2008) 0.96
Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology (2011) 0.96
Exosites mediate the anti-inflammatory effects of a multifunctional serpin from the saliva of the tick Ixodes ricinus. FEBS J (2009) 0.96
Tsetse fly saliva accelerates the onset of Trypanosoma brucei infection in a mouse model associated with a reduced host inflammatory response. Infect Immun (2006) 0.95
Experimental expansion of the regulatory T cell population increases resistance to African trypanosomiasis. J Infect Dis (2008) 0.95
Infection stage-dependent modulation of macrophage activation in Trypanosoma congolense-resistant and -susceptible mice. Infect Immun (2002) 0.94
Occurrence of two 5-aminolevulinate biosynthetic pathways in Streptomyces nodosus subsp. asukaensis is linked with the production of asukamycin. J Bacteriol (2006) 0.93
Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur J Immunol (2013) 0.93
Purification and characterization of heterologously expressed nitrilases from filamentous fungi. Appl Microbiol Biotechnol (2011) 0.92
Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A. Immunol Lett (2007) 0.92
Identification of a functional Antigen5-related allergen in the saliva of a blood feeding insect, the tsetse fly. Insect Biochem Mol Biol (2009) 0.91
Similar inflammatory DC maturation signatures induced by TNF or Trypanosoma brucei antigens instruct default Th2-cell responses. Eur J Immunol (2011) 0.91
VSG-GPI anchors of African trypanosomes: their role in macrophage activation and induction of infection-associated immunopathology. Microbes Infect (2002) 0.91
The role of monocytes in the development of Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome. Immunobiology (2013) 0.90
IL-10 limits production of pathogenic TNF by M1 myeloid cells through induction of nuclear NF-κB p50 member in Trypanosoma congolense infection-resistant C57BL/6 mice. Eur J Immunol (2011) 0.90
Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood (2002) 0.90
Identification of a tsetse fly salivary protein with dual inhibitory action on human platelet aggregation. PLoS One (2010) 0.89
Instruction of myeloid cells by the tumor microenvironment: Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. Oncoimmunology (2012) 0.89
Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology (2012) 0.88